News
OKYO
1.350
-3.57%
-0.050
OKYO Pharma to Participate in Jefferies Global Healthcare Conference
TipRanks · 1d ago
Here's Why We're Not Too Worried About OKYO Pharma's (NASDAQ:OKYO) Cash Burn Situation
Simply Wall St · 3d ago
Weekly Report: what happened at OKYO last week (1102-1106)?
Weekly Report · 4d ago
OKYO Pharma to Present at Stifel 2026 Healthcare Conference
TipRanks · 11/05 13:14
Weekly Report: what happened at OKYO last week (1026-1030)?
Weekly Report · 11/02 09:16
Weekly Report: what happened at OKYO last week (1019-1023)?
Weekly Report · 10/26 09:16
Weekly Report: what happened at OKYO last week (1012-1016)?
Weekly Report · 10/19 09:16
Weekly Report: what happened at OKYO last week (1005-1009)?
Weekly Report · 10/12 09:17
Analyst Reaffirms Buy on OKYO as Urcosimod Enters Pivotal Phase 3; $5 Price Target Maintained
TipRanks · 10/06 16:25
OKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal Pain
NASDAQ · 10/06 12:25
Okyo Pharma announces first patients enrolled in NEPTUNE trial
TipRanks · 10/06 11:10
Weekly Report: what happened at OKYO last week (0928-1002)?
Weekly Report · 10/05 09:17
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Key Ophthalmic Conferences
TipRanks · 09/29 11:27
Weekly Report: what happened at OKYO last week (0921-0925)?
Weekly Report · 09/28 09:16
Weekly Report: what happened at OKYO last week (0914-0918)?
Weekly Report · 09/21 09:16
Weekly Report: what happened at OKYO last week (0907-0911)?
Weekly Report · 09/14 09:17
OKYO Pharma to Showcase Urcosimod at Key European Ophthalmology Forums
TipRanks · 09/09 11:28
OKYO Pharma to Highlight Urcosimod Progress at Cantor Global Healthcare Conference
TipRanks · 09/08 11:28
Weekly Report: what happened at OKYO last week (0831-0904)?
Weekly Report · 09/07 09:16
Weekly Report: what happened at OKYO last week (0824-0828)?
Weekly Report · 08/31 09:17
More
Webull provides a variety of real-time OKYO stock news. You can receive the latest news about OKYO PHARMA LTD through multiple platforms. This information may help you make smarter investment decisions.
About OKYO
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.